Category: Redefining Every Stage Investments (RESI)

The Redefining Every Stage Investments (RESI) Conference is an ongoing conference series that provides an international venue for life science companies across Biotech, Medtech, Diagnostics and Healthcare IT and to source investors from around the globe, create relationships, and eventually, secure funding.

Free Fundraising Bootcamp Today!

~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

All Life Science Nation (LSN)’s services are dedicated to facilitating connections between early-stage life science companies and investors/strategic partners. To advance the mission of connecting companies and capital, as well as help more life science entrepreneurs prepare for global fundraising, we have organized and hosted several free Fundraising Bootcamps this summer.

sign-up-for-free
These free Fundraising Bootamps are not only great sessions to familiarize oneself with LSN’s services that can be leveraged for fundraising efforts, such as the LSN Investor Database or RESI Partnering Week, September 13-17, but they also provide fundamental insights regarding the fundraising process, covering topics including:

  • Top 10 Common Myths in Fundraising
  • How to Prepare Your Messaging for Investor Outreach
  • How to Prepare for Meetings

Sign up for today’s free Fundraising Bootcamp at 2 PM EDT!

The Reglagene Story and How They Learned to Tell It

~ Next Phase Admin ~ Leave a comment

By Rory McCann, Marketing Manager & Conference Producer, LSN

Like most scientist-entrepreneurs, Reglagene CEO, Richard Austin thought the compelling story of his company and their precision chemotherapy technology would be enough to get the attention of investors. He quickly learned the importance of marketing the company and telling their story was also integral to their growth. His early experiences with RESI served as classroom, arena, and runway to success.

In our interview, Richard references the education he received from Life Science Nation CEO, Dennis Ford. Dennis is hosting the Global Roadshow Prep Course: a hands-on, comprehensive, one-day course designed to set up the early-stage life science executive for success as they conduct their global fundraise. Each class is open to 24 early-stage, fundraising entrepreneurs and includes premier access to RESI Partnering Week, September 13-17.

The Global Roadshow Prep Course takes place Friday, September 3 and September 10. View the agenda and sign up to jumpstart your fundraising through telling your story and connecting with the right investors for you!

Saving Critical Time for Blood Cancer Detection & Decisions with AI Interview with Andrea Wang, MS, CEO & Co-Founder, AHEAD Medicine

~ Next Phase Admin ~ Leave a comment

By Erika Wu, Business Development Representative, LSN

Launching recent partnerships with Mayo Clinic and Roswell Park Comprehensive Cancer Center, Andrea Wang and her team at AHEAD Medicine is paving the way for blood cancer detection and clinical decisions using AI-powered analytics.

As a 9-time RESI attendee, panelist, and Innovator Pitch Challenge (IPC) participant, we are excited to see where AHEAD is going next. Get in front of AI investors at Digital RESI AI (September 16-17) by pitching your company at  Innovator’s Pitch Challenge!

Deadline is Tomorrow – Gain More Exposure at RESI Partnering Week’s Innovator’s Pitch Challenge

~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Life Science Nation’s next RESI Partnering Week is coming up in less than a month, which means an intensive week of 1-on-1 virtual partnering meetings, panels, workshops, and of course, the Innovator’s Pitch Challenge(IPC), all taking place September 13-17.

Since last year’s introduction to the IPC, its popularity has skyrocketed and is now one of the most anticipated sections of the Digital RESI Partnering Week menu. With its unique format, selected IPC participants can showcase their technology through a dedicated landing page, which will include a pre-recorded pitch video. Each company will participate in a live Q&A session, joined by a panel of investors and industry experts who will have reviewed the pitch video beforehand.

Below are the companies who have been selected for the upcoming IPC so far across all 3 conferences of RESI Partnering Week – Digital RESI, RESI AI, and RESI Longevity.

Whether you are part of a startup looking to boost exposure or an investor seeking novel innovations that fit your interests, you do not want to miss out on the upcoming RESI Partnering Week. Register and apply now! Applications must be in by Friday, August 20.

Partnering Opens Next Week

~ Next Phase Admin ~ Leave a comment

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Partnering for RESI Partnering Week, taking place September 13-17, launches Monday, giving companies a chance to connect with investors. The LSN Partnering Platform offers startups an unprecedented opportunity to search for and identify investors that are a fit for them based on sector, stage of development and other helpful criteria. Successful partnering takes a lot of work, and the companies that book the most meetings send, on average, over 100 meeting requests to relevant investors, followed by frequent follow-ups. We will be offering free partnering tutorials for registered attendees in the weeks before the conference takes place. Take a look at the registered investors below, and make sure to register now before partnering launches!

Confirmed RESI Partnering Week Investors

Hot Investor Mandate: Private Life Science Investment Firm Interested in Global Therapeutics Companies in Immuno-Oncology, Metabolic Disease, and More

~ Next Phase Admin ~ Leave a comment

A private life science investment firm with a presence in USA, Canada, and Western Europe, looks to make investments into privately held companies and while the firm can be flexible in terms of allocation size, most investments fall in the $.5-$3million range. The firm is open to investing in companies located around the globe.

The firm is currently looking for therapeutics companies across all indication areas with particular attention to metabolic diseases (including type II diabetes), immunoncology, aging, and infectious diseases. The firm is interested in pre-clinical stage companies that have a lead asset established as well as companies in early clinical trials. The firm is open to all molecule types that meet this criteria. The firm is generally not interested in next generation cytotoxic chemotherapies, therapies for Alzheimer’s Disease, or therapies for cardiovascular indications.

The firm acts as hands-on investors who contribute substantially to the operation of their portfolio companies, often supplementing management with a network of drug developers and specialists in regulatory affairs, clinical affairs, manufacturing, and other subspecialties.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Family Office with Over 30 Years of Experience Invests in Early-Stage Medtech & Digital Health Companies Based in North America and Europe

~ Next Phase Admin ~ Leave a comment

A family office founded over 30 years ago has recently been restarted, and has recently transitioned to have a stronger healthcare focus after coming out of dormancy and is seeking to make equity investments in the $200K – $2M USD range. The firm is a multi-stage longer term oriented investor interested in new and more seasoned emerging growth companies addressing a broad range of Healthcare and Medical products and services opportunities. The firm invests in companies based in North America and Europe and is actively seeking new investment opportunities.

The firm is interested in Medtech and Healthcare IT projects that are transformative and disruptive within their fields. The firm is not interested in therapeutics, vaccines, molecules, or any healthcare projects with undefined regulatory approval cycles. Otherwise, the firm is rather opportunistic within the Medtech and Healthcare IT sectors.

When investing, the firm seeks a board seat and prefers to get involved with the management team. As a result, the firm prefers a management team that is willing to work with them together as partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.